HIGH TIDE INC (HITI) Stock Fundamental Analysis
NASDAQ:HITI - Nasdaq - CA42981E4013 - Common Stock - Currency: USD
Taking everything into account, HITI scores 4 out of 10 in our fundamental rating. HITI was compared to 194 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of HITI get a neutral evaluation. Nothing too spectacular is happening here. HITI has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
HITI had negative earnings in the past year.
In the past year HITI had a positive cash flow from operations.
HITI had negative earnings in each of the past 5 years.
HITI had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of HITI (-1.76%) is better than 79.46% of its industry peers.
Looking at the Return On Equity, with a value of -3.03%, HITI belongs to the top of the industry, outperforming 82.16% of the companies in the same industry.
HITI has a Return On Invested Capital of 6.12%. This is amongst the best in the industry. HITI outperforms 84.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.76% | ||
| ROE | -3.03% | ||
| ROIC | 6.12% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HITI's Operating Margin of 2.93% is fine compared to the rest of the industry. HITI outperforms 77.84% of its industry peers.
HITI has a Gross Margin (27.28%) which is in line with its industry peers.
In the last couple of years the Gross Margin of HITI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.93% | ||
| PM (TTM) | N/A | ||
| GM | 27.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so HITI is destroying value.
HITI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HITI has more shares outstanding
HITI has a better debt/assets ratio than last year.
2.2 Solvency
HITI has an Altman-Z score of 3.01. This indicates that HITI is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.01, HITI is doing good in the industry, outperforming 73.51% of the companies in the same industry.
HITI has a debt to FCF ratio of 2.89. This is a good value and a sign of high solvency as HITI would need 2.89 years to pay back of all of its debts.
HITI has a Debt to FCF ratio of 2.89. This is amongst the best in the industry. HITI outperforms 91.35% of its industry peers.
HITI has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
HITI has a worse Debt to Equity ratio (0.36) than 61.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 2.89 | ||
| Altman-Z | 3.01 |
ROIC/WACC0.73
WACC8.44%
2.3 Liquidity
HITI has a Current Ratio of 1.40. This is a normal value and indicates that HITI is financially healthy and should not expect problems in meeting its short term obligations.
HITI's Current ratio of 1.40 is on the low side compared to the rest of the industry. HITI is outperformed by 78.38% of its industry peers.
A Quick Ratio of 0.92 indicates that HITI may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.92, HITI is doing worse than 83.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 0.92 |
3. Growth
3.1 Past
HITI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.00%.
The Revenue for HITI has decreased by -13.77% in the past year. This is quite bad
The Revenue has been growing by 75.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-240%
Revenue 1Y (TTM)-13.77%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%8.8%
3.2 Future
HITI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 74.44% yearly.
The Revenue is expected to grow by 13.54% on average over the next years. This is quite good.
EPS Next Y132.06%
EPS Next 2Y115.53%
EPS Next 3Y121.75%
EPS Next 5Y74.44%
Revenue Next Year14.03%
Revenue Next 2Y15.26%
Revenue Next 3Y15.03%
Revenue Next 5Y13.54%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
HITI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 182.22 indicates a quite expensive valuation of HITI.
Based on the Price/Forward Earnings ratio, HITI is valued a bit cheaper than 72.97% of the companies in the same industry.
HITI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.68.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 182.22 |
4.2 Price Multiples
HITI's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HITI is cheaper than 90.81% of the companies in the same industry.
HITI's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HITI is cheaper than 90.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.54 | ||
| EV/EBITDA | 7.61 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as HITI's earnings are expected to grow with 121.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y115.53%
EPS Next 3Y121.75%
5. Dividend
5.1 Amount
HITI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.59
+0.01 (+0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners9.23%
Inst Owner Change64.78%
Ins Owners8.82%
Ins Owner ChangeN/A
Market Cap209.53M
Analysts80
Price Target4.36 (68.34%)
Short Float %5.44%
Short Ratio5.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-88.08%
Min EPS beat(2)-315.76%
Max EPS beat(2)139.6%
EPS beat(4)3
Avg EPS beat(4)2.25%
Min EPS beat(4)-315.76%
Max EPS beat(4)139.6%
EPS beat(8)7
Avg EPS beat(8)43.06%
EPS beat(12)10
Avg EPS beat(12)24.03%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.53%
Min Revenue beat(2)1.15%
Max Revenue beat(2)1.9%
Revenue beat(4)2
Avg Revenue beat(4)-0.29%
Min Revenue beat(4)-3.51%
Max Revenue beat(4)1.9%
Revenue beat(8)6
Avg Revenue beat(8)1.18%
Revenue beat(12)10
Avg Revenue beat(12)9.7%
Revenue beat(16)13
Avg Revenue beat(16)7.54%
PT rev (1m)0.41%
PT rev (3m)-4.18%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-57.15%
EPS NY rev (3m)-57.15%
Revenue NQ rev (1m)-1.21%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 182.22 | ||
| P/S | 0.57 | ||
| P/FCF | 11.54 | ||
| P/OCF | 8.38 | ||
| P/B | 2.08 | ||
| P/tB | 5.9 | ||
| EV/EBITDA | 7.61 |
EPS(TTM)-0.04
EYN/A
EPS(NY)0.01
Fwd EY0.55%
FCF(TTM)0.22
FCFY8.66%
OCF(TTM)0.31
OCFY11.94%
SpS4.54
BVpS1.25
TBVpS0.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.76% | ||
| ROE | -3.03% | ||
| ROCE | 8.29% | ||
| ROIC | 6.12% | ||
| ROICexc | 8.09% | ||
| ROICexgc | 21.29% | ||
| OM | 2.93% | ||
| PM (TTM) | N/A | ||
| GM | 27.28% | ||
| FCFM | 4.94% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
F-Score6
Asset Turnover2.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 2.89 | ||
| Debt/EBITDA | 1.27 | ||
| Cap/Depr | 38.4% | ||
| Cap/Sales | 1.87% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.32% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.4 | ||
| Quick Ratio | 0.92 | ||
| Altman-Z | 3.01 |
F-Score6
WACC8.44%
ROIC/WACC0.73
Cap/Depr(3y)28.99%
Cap/Depr(5y)34.63%
Cap/Sales(3y)1.88%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-240%
EPS Next Y132.06%
EPS Next 2Y115.53%
EPS Next 3Y121.75%
EPS Next 5Y74.44%
Revenue 1Y (TTM)-13.77%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%8.8%
Revenue Next Year14.03%
Revenue Next 2Y15.26%
Revenue Next 3Y15.03%
Revenue Next 5Y13.54%
EBIT growth 1Y372.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year489.9%
EBIT Next 3Y135.82%
EBIT Next 5Y83.86%
FCF growth 1Y76.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.04%
OCF growth 3YN/A
OCF growth 5YN/A